Compare CFND & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFND | DARE |
|---|---|---|
| Founded | N/A | 2015 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 16.6M |
| IPO Year | 2024 | 2014 |
| Metric | CFND | DARE |
|---|---|---|
| Price | $2.21 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 27.5K | ★ 117.9K |
| Earning Date | N/A | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,807,885.00 |
| Revenue This Year | N/A | $116.54 |
| Revenue Next Year | N/A | $201.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.04 | $0.61 |
| 52 Week High | $6.70 | $3.78 |
| Indicator | CFND | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 31.75 | 51.12 |
| Support Level | $2.04 | $0.70 |
| Resistance Level | $3.48 | $0.74 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 10.00 | 77.44 |
C1 Fund Inc is a non-diversified, closed-end management investment company. The Adviser provides day-to-day investment management services to the Company, which is classified as non-diversified under the Investment Company Act. The Company's investment objective is to maximize its portfolio's total return by principally investing in privately held equity and equity-linked securities of digital asset services and technology companies. Its investments in equity securities include common and preferred shares, securities convertible into common shares, warrants and rights to subscribe to or purchase common shares, and common shares carrying a warrant or right.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.